Fusion Pharmaceuticals Inc. Deferred Tax Assets, Net of Valuation Allowance
Fusion Pharmaceuticals Inc. had Deferred Tax Assets, Net of Valuation Allowance of $8.71 million as of 2023-12-31, per its 10-K filed 2024-03-20.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2024-03-20
- 2023-12-31: Deferred Tax Assets, Net of Valuation Allowance $8.71M.
- 2022-12-31: Deferred Tax Assets, Net of Valuation Allowance $6.19M.
- 2021-12-31: Deferred Tax Assets, Net of Valuation Allowance $3.23M.
- 2020-12-31: Deferred Tax Assets, Net of Valuation Allowance $862.00K.
| Period end | Deferred Tax Assets, Net of Valuation Allowance |
|---|---|
| 2023-12-31 | $8.71M 10-K · filed 2024-03-20 |
| 2022-12-31 | $6.19M 10-K · filed 2024-03-20 |
| 2021-12-31 | $3.23M 10-K · filed 2023-03-16 |
| 2020-12-31 | $862.00K 10-K · filed 2022-03-17 |
| 2019-12-31 | $78.00K 10-K · filed 2021-03-25 |